Complete financial analysis of Certara, Inc. (CERT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Certara, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Balmer Lawrie & Co. Ltd. (BALMLAWRIE.NS) Income Statement Analysis – Financial Results
- YCIH Green High-Performance Concrete Company Limited (1847.HK) Income Statement Analysis – Financial Results
- AlphaTime Acquisition Corp (ATMCW) Income Statement Analysis – Financial Results
- C4X Discovery Holdings plc (C4XD.L) Income Statement Analysis – Financial Results
- Bigbloc Construction Limited (BIGBLOC.BO) Income Statement Analysis – Financial Results
Certara, Inc. (CERT)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.certara.com
About Certara, Inc.
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 354.34M | 335.64M | 286.10M | 243.53M | 208.51M | 163.72M |
| Cost of Revenue | 141.02M | 132.58M | 111.62M | 100.77M | 79.77M | 71.04M |
| Gross Profit | 213.32M | 203.07M | 174.49M | 142.77M | 128.74M | 92.68M |
| Gross Profit Ratio | 60.20% | 60.50% | 60.99% | 58.62% | 61.74% | 56.61% |
| Research & Development | 34.17M | 28.21M | 20.38M | 19.64M | 11.63M | 10.48M |
| General & Administrative | 95.39M | 71.77M | 79.54M | 88.48M | 47.93M | 43.39M |
| Selling & Marketing | 32.02M | 27.41M | 20.14M | 19.20M | 10.73M | 9.42M |
| SG&A | 127.41M | 99.18M | 99.68M | 107.68M | 58.66M | 52.81M |
| Other Expenses | 92.51M | 43.16M | 40.85M | 39.86M | 38.84M | -107.00K |
| Operating Expenses | 254.09M | 170.55M | 160.91M | 167.19M | 109.13M | 97.33M |
| Cost & Expenses | 395.11M | 303.12M | 272.53M | 267.95M | 188.90M | 168.37M |
| Interest Income | 0.00 | 17.77M | 16.84M | 25.30M | 28.00M | 0.00 |
| Interest Expense | 22.92M | 17.77M | 16.84M | 25.30M | 28.00M | 27.80M |
| Depreciation & Amortization | 56.07M | 52.47M | 45.12M | 42.75M | 41.56M | 37.01M |
| EBITDA | 23.84M | 89.00M | 58.58M | 17.87M | 60.41M | 32.25M |
| EBITDA Ratio | 6.73% | 26.52% | 20.47% | 7.34% | 28.97% | 19.70% |
| Operating Income | -40.77M | 32.52M | 13.58M | -24.89M | 19.61M | -4.65M |
| Operating Income Ratio | -11.51% | 9.69% | 4.75% | -10.22% | 9.41% | -2.84% |
| Total Other Income/Expenses | -14.37M | -13.77M | -16.95M | -25.76M | -28.76M | -27.91M |
| Income Before Tax | -55.14M | 18.76M | -3.38M | -50.18M | -9.15M | -32.56M |
| Income Before Tax Ratio | -15.56% | 5.59% | -1.18% | -20.61% | -4.39% | -19.89% |
| Income Tax Expense | 214.00K | 4.02M | 9.89M | -784.00K | -225.00K | 697.00K |
| Net Income | -55.36M | 14.73M | -13.27M | -49.40M | -8.93M | -33.26M |
| Net Income Ratio | -15.62% | 4.39% | -4.64% | -20.28% | -4.28% | -20.31% |
| EPS | -0.35 | 0.09 | -0.09 | -0.32 | -0.06 | -0.25 |
| EPS Diluted | -0.35 | 0.09 | -0.09 | -0.32 | -0.06 | -0.25 |
| Weighted Avg Shares Out | 158.94M | 156.88M | 149.84M | 152.98M | 157.34M | 132.41M |
| Weighted Avg Shares Out (Dil) | 158.94M | 159.35M | 149.84M | 152.98M | 157.34M | 132.41M |
Why Certara Is A Buy For 2023
Why Certara's Shares Rose 37.7% This Week
Certara, Inc. (CERT) Q3 Earnings Miss Estimates
Certara Inc. (CERT) Q3 2022 Earnings Call Transcript
Certara Reports Third Quarter 2022 Financial Results
Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase
Certara to Participate in Upcoming Investor Conferences
Reveal Announces New Partnership with Grant Thornton Australia
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara's Software for Evaluating Regulatory Submissions
Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022
Source: https://incomestatements.info
Category: Stock Reports